Upfront Briefing
The Senate picked up the baton on BINSA over the weekend, which means the licensing structure that has quietly financed half the sector's pipeline is now a Treasury review question rather than a House talking point. Congressional findings peg 2025 cross-border out-licensing at roughly $136B, up from under $5B in 2020 — a lot of term sheets to re-paper. Elsewhere, Grail finally got a date — 23 September, in front of a panel that will be asked whether strong secondaries can carry a failed primary. Two very different regulators, same question: how much benefit of the doubt is left?
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,757.6 |
0.6% |
13.1% |
| Nasdaq 100 |
29,722.3 |
1.2% |
17.9% |
| Russell 2000 |
3,034.5 |
1.1% |
21.0% |
| Healthcare (XLV) |
165.7 |
0.8% |
6.5% |
| Biotech (XBI) |
157.4 |
1.9% |
29.5% |
| Nasdaq Biotech (NBI) |
6,781.8 |
1.8% |
18.8% |
| Clinical Trials (BBC) |
52.5 |
0.9% |
39.6% |
|
- Biotech took the duration trade hardest, XBI +1.9% against the S&P's +0.6%, with the IPO tape corroborating: Latigo (LTGO) and BlossomHill (BLSM) both debuted oversubscribed Friday, each raising at least 30% more than planned.
- The July payrolls print did the macro work — the economy shed 23,000 jobs against consensus of +80,000, unemployment ticked to 4.1%, and the market took a September Fed hike off the table, sending the S&P to a record 7,757.63 close and capping its best week since April.
- Market data: U.S. cash close Friday, 7 August 2026.
The Big 3
|
1
|
BINSA reaches the Senate, putting China licensing under Treasury review
|
- Senators Elissa Slotkin (D-MI) and Pete Ricketts (R-NE) introduced the Biotech Investment National Security Act, a companion to the June House bill, which would add pharmaceutical development, biologics manufacturing and clinical research to the COINS Act's screened-sector list.
- Why it matters: BINSA would fold licensing deals, joint ventures and equity stakes with Chinese counterparties into Treasury's screening regime — the first bill to reach past equity and touch the pure licensing structure that has carried most of the sector's China sourcing. Congressional findings put 2025 cross-border out-licensing at roughly $136B, against under $5B in 2020, and sponsors named the BMS/Hengrui $15.2B co-development pact as the archetype. Senate companion status moves this from message bill to live calendar risk, and every Hengrui-, Innovent- or 3SBio-sourced asset now carries a diligence line item. Industry fought hard for the FIRRMA licensing carve-out and will fight this too — enactment is nowhere near priced.
- Source: Endpoints
- More: Senate release; Bill text
|
|
2
|
FDA sets 23 September panel for Grail's Galleri after failed trial
|
- Grail (GRAL) said the FDA's Molecular and Clinical Genetics Panel will meet 23 September to review the premarket approval application for Galleri, filed 29 January and anchored on a trial that missed its primary endpoint.
- Why it matters: This is the first advisory committee any multi-cancer early detection test has faced, and it lands on a submission whose anchor study fell short. NHS-Galleri enrolled 142,000 and failed to show a significant Stage III-IV reduction; the PMA leans instead on PATHFINDER 2 (n=25,490) and first-round NHS data. TD Cowen puts approval odds at 75% and notes the agency follows its panels roughly 80% of the time, which makes roster composition the tradeable variable between now and September. Galleri did 61,000 tests last quarter, up 35% year over year — commercial traction exists without a label. A hostile panel reprices Exact, Guardant and every private MCED round sitting behind them.
-
Source:
Endpoints
- More: MedTech Dive; PR
|
| 3 | Innovent takes China rights to Daiichi Sankyo's Vanflyta |
- Innovent Biologics (01801.HK) and Daiichi Sankyo (TSE: 4568) signed an exclusive agreement giving Innovent sole commercialization rights to Vanflyta (quizartinib) in China for newly diagnosed FLT3-ITD positive AML, with Daiichi retaining development, manufacturing and supply. Economics were not disclosed.
- Why it matters: Undisclosed economics cap how much of this anyone can underwrite, but the strategic logic is legible. Daiichi has never made Vanflyta work commercially — ¥4.5B (~$29M) globally in FY2024 against Astellas' ¥68B for Xospata — and is handing China distribution to the partner with 20 marketed products and a built oncology sales force. QuANTUM-First carries the asset's case: median OS of 31.9 months versus 15.1 on control. Note the direction of travel here. This is Japanese IP flowing into Chinese commercialization, the mirror image of the BINSA trade above, and it sits outside that bill's perimeter entirely. Innovent is the accessible leg.
- Source: PR
- More: Daiichi Sankyo; Fierce Pharma
|
Everything Else that broke
- Otsuka presented two-year VISIONARY eGFR data for Voyxact at GlomCon Hawaii — annualized slope +0.3 vs (4.2) mL/min/1.73m²/yr on placebo, a +9.2 treatment difference at 24 months — supporting its rolling sBLA for traditional approval. — BioSpace
- NRx said FDA cleared first-cycle review of its preservative-free ketamine ANDA; packaging remains. — PR
- BioMarin ended development of BMN 401 across all indications after mixed Phase III data, writing off a $270M rare-disease asset. — Fierce Biotech
- Nicox's partner Ocumension filed a China NDA for NCX 470. — PR
- Intellia identified a genetic suspect behind liver safety signals in its ATTR program. — BioSpace
- Replimune is preparing Tudriqev's advanced melanoma launch with $1.3B peak-sales expectations in view. — BioSpace
- Entera said FDA aligned on a 12-month registrational Phase III path for EB613. — PR
- RiboX won FDA IND clearance for RXIM002, a circular RNA-based in vivo CAR therapy. — PR
- Vistagen's anxiety nasal spray failed to beat placebo even at a double dose, and the company is again pointing to a subpopulation as its path to FDA. — Fierce Biotech
- aTyr restructured and narrowed focus around efzofitimod in ILD. — PR
- WuXi AppTec won a preliminary injunction in its 1260H case. — BioCentury
- Ensoma cut jobs and paused preclinical programs to focus on one lead gene therapy. — Fierce Biotech
- AB Science completed €14.2M in capital increases to bolster runway. — PR
- Akeso dosed the first patient in Phase II for AK146D1 plus ivonescimab in breast cancer. — PR
- Arcturus (ARCT) and CSL Seqirus terminated their 2022 sa-mRNA collaboration, returning global KOSTAIVE and infectious-disease vaccine rights to Arcturus for a $12M cash payment plus ~$16M of released R&D-credit liabilities. — BioSpace
- Vedanta banked $60M — a $40M round from AMR Action Fund and BNP Paribas AM Alts plus $20M of BARDA contract funding — with Phase 3 RESTORATiVE303 past 80% enrolment and topline VE303 efficacy guided to 1H27. — Endpoints
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Innovent took exclusive China commercialization rights to Daiichi Sankyo's Vanflyta for FLT3-ITD positive AML; terms undisclosed (see The Big 3). — PR
- Arcturus and CSL Seqirus unwound a collaboration originally carrying $200M upfront and up to $4.3B in milestones, settling for $12M cash and ~$16M of released liabilities. — BioSpace
VC / Private Financings
- Vedanta Biosciences closed a $40M round led by existing backers AMR Action Fund and BNP Paribas Asset Management Alts (~$18M in Q1, ~$22M in Q2), alongside $20M of non-dilutive BARDA funding. — Endpoints
IPOs / Follow-Ons
- Braveheart Bio (BRVE) closed its upsized IPO at 24,437,500 shares priced at $18.00 including the full 3,187,500-share greenshoe, taking gross proceeds to $439.9M. — BioPharma Dive
- Latigo (LTGO) and BlossomHill (BLSM) both debuted Friday well through expectations, each raising at least 30% more than planned — Latigo at $345.6M on 19.2M shares at $18.00, BlossomHill at $150M on ~9.4M shares at $16.00. — Fierce Biotech
Academic Corner
- Faecal transplant raised peanut tolerance roughly sixfold in a small Phase 1 food-allergy trial out of Boston Children's. — Fierce Biotech
|
